University of Florida Researchers Developed Lung Treatment

The new drug candidate, ALT-100, aims to reduce lung inflammation without suppressing the patient's immune system.

Updated on Sept. 29, 2026 in Asthma

A close-up of a glass scientific pipette entering a liquid-filled beaker in a sterile laboratory setting. — University of Florida researchers have developed a new drug candidate, ALT-100, designed to target and reduce acute lung inflammation without systemic immune suppression. AI Illustration. Upload story photo >

Live Poll

Does new biomedical research increase your trust in the future of medical treatments?

Researchers at the University of Florida have developed a new treatment called ALT-100 designed to address lung inflammation. This innovation seeks to provide a therapeutic option for conditions where current medical interventions are insufficient.

Why it matters

Current treatments for acute respiratory distress syndrome often fail to adequately support critically ill patients, as inflammation causes dangerous fluid buildup in the lungs. By targeting signaling pathways without systemic immune suppression, this drug could offer a new approach for intensive care units.

ALT-100 is designed to target specific inflammatory signaling pathways in the lungs. No drug is currently approved by the FDA for the treatment of acute respiratory distress syndrome.

The players

The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology

This facility serves as a primary hub for biomedical research and technological advancement within the University of Florida system.

University of Florida

A public land-grant research university based in Gainesville that maintains a broad portfolio of medical and scientific investigations.

The details

The treatment works by targeting a central signaling pathway involved in inflammatory injury, functioning through an antibody that acts similarly to Humira. It is intended to manage inflammation in patients with acute respiratory distress syndrome, where fluid accumulation currently presents a major clinical challenge.

September 2026: Researchers discussed the potential of ALT-100 in a media feature.

The Big Picture

This research follows the precedent set by the development of Humira in using targeted antibody therapy to manage inflammatory pathways. It signals a move toward more precise molecular interventions in intensive care settings.

Patients suffering from acute respiratory distress syndrome may eventually gain access to a targeted therapy that manages lung inflammation without the broad risks of immune suppression. The treatment remains in clinical trials and is not yet available for patient use.

The takeaway

Targeted antibody therapies continue to evolve as a primary strategy for controlling severe inflammatory conditions in hospital settings. Future clinical trial results will determine whether ALT-100 can safely transition from the laboratory to intensive care units.